Tag:

WuXi PharmaTech

Latest Headlines

Latest Headlines

UPDATED: WuXi files a 406 extension with U.S. SEC. What's the secret?

WuXi PharmaTech sought and has been approved for an extension under U.S. Securities and Exchange Commission Rule 406 to keep confidential treatment of information excluded from Form F-1 filed on July 24, 2007, as amended, according to an order filed June 17.

WuXi signs on to help ReGenX manufacture gene therapies

Chinese CRO WuXi PharmaTech is joining forces with the gene therapy experts at ReGenX Bio to hammer out a manufacturing process for the company's potential one-time treatments.

WuXi lands a role in the U.K.'s plot to sequence 100,000 genomes

WuXi PharmaTech's NextCODE secured a spot among the companies and research institutions taking part in Genomics England, contending for a lead role in the group's ambitious effort to sequence the genomes of 100,000 people.

Heavyweight Chinese consortium buys San Diego-based Ambrx

A heavyweight consortium of Chinese biomedical- and healthcare-focused funds said it would acquire San Diego-based biotech Ambrx, which abandoned an initial public offering last year, in a deal that opens a path to cutting-edge candidates in oncology therapies.

WuXi posts another big quarter as it faces a big decision

WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.

WuXi weighs going private with a deal on the table

WuXi PharmaTech, China's largest CRO, is considering an offer that would take it private at a sizable premium, forming a committee of independent advisers as it plots its next move.

WuXi starts work in China on yet another cell-line manufacturing facility

Wuxi PharmaTech, which is making a big push into cell line manufacturing, has started work on a $150 million plant in China, after already starting on new facilities in the U.S.

WuXi starts up construction of China's largest biologics plant

WuXi Biologics is embarking on construction of what will be the biggest biologics plant in China once it's completed--an event the company expects by the end of next year.

Busy WuXi starts construction on China's largest biologics manufacturing plant

WuXi Biologics said it has begun construction of a $150 million manufacturing facility for its biologics unit, which it lists as being the largest biologics manufacturing facility of any kind in China.

WuXi's CEO moves to take the CRO private

WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.